Project Grant R21DA066520
- Federal Grant Award Summary The University of Utah received a $462,000 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded June 1, 2026, with completion targeted for April 30, 2031. The project, "Illuminating Neuropeptide Modulation of Substance Abuse Withdrawal: Novel Photochemical Tools for Precision Control," will develop engineered photochemical probes to investigate the neuropeptidergic mechanisms...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Kentucky Research Foundation a $2.175 million Project Grant on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized controlled clinical trial evaluating non-abstinence treatment outcomes for methamphetamine use disorder (MUD). The research deliverables include a 24-week trial (12 weeks of treatment plus 12 weeks of follow-up)...
- Federal Grant Award Summary The National Institute on Drug Abuse awarded a $206,180 Project Grant to The Regents of the University of California, San Francisco, effective September 1, 2025, through August 31, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). The ACCOMPLISH (Applied Coaching of Computational Learners in Substance Use and HIV) Mentoring Program delivers research services focused on investigating the intersection of methamphetamine use, HIV infection, and...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Miami's Office of Research Administration—School of Medicine a $164,190 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) effective August 19, 2026, with completion targeted for March 31, 2030. This research initiative investigates the mechanistic underpinnings of cognitive impairment resulting from concurrent HIV infection and methamphetamine (METH) use,...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Diego a $4.95 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) for the Brain-Focused Research on Antiretrovirals and Methamphetamine (BRAIN-FRAME) initiative. The award, effective May 15, 2026, through March 31, 2031, supports a multidisciplinary research program investigating how long-acting injectable antiretroviral therapy (LAI-ART) and...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded $516,914 to the University of Miami's Office of Research Administration—School of Medicine Division on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the molecular mechanisms underlying HIV infection and latency in brain pericytes, with specific emphasis on the synergistic effects of methamphetamine use. The project, which extends through February 28, 2031, will...
- Federal Grant Award Summary Award Details: The National Institute on Drug Abuse (NIDA) awarded a $3.72 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Chestnut Health Systems Inc. on September 15, 2025, with completion scheduled for May 31, 2030. Products and Services: This hybrid effectiveness-implementation trial will test and scale the Just Care for Families (JCFF) intervention, a multicomponent service model designed to address the interrelated...
- Federal Grant Award Summary The University of Montana received a $538,400 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 15, 2025, with completion targeted for August 31, 2030. Led by Principal Investigators Dr. Rachel Severson and Alex Sobin and based at the University of Montana's Living Lab and Spectrum Discovery Area, "The Changing Brain" project addresses health science education...
- Federal Grant Award Summary Chestnut Health Systems Inc. received a $1.33 million Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded September 15, 2025, with completion targeted for May 31, 2030. The award funds the Recovery Management Checkup Scalability and Sustainability (RMC-SS) Hybrid Experiment, a Type 2 effectiveness-implementation trial designed to integrate and evaluate Recovery Management Checkups (RMC)—an...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded the University of Pennsylvania a $885,939 Project Grant effective July 1, 2026, through May 31, 2031, to test the effectiveness of a remote intervention designed to reduce HIV and Hepatitis C Virus (HCV) infection risk in rural areas of the United States. The five-year initiative will deliver a virtual social intervention convened via Zoom that brings...
The University of Utah received a $423,500 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test the feasibility and preliminary effectiveness of a remote collaborative care-facilitated contingency management-cardiac rehabilitation program for individuals with methamphetamine-associated cardiopulmonary conditions. The award, dated July 15, 2026, with a completion date of June 30, 2028, addresses the growing public health crisis of methamphetamine use and its severe cardiovascular consequences, particularly in rural populations. The program will integrate cardiology and addiction medicine expertise through a collaborative care model supported by intensive care management and peer navigation, utilizing evidence-based contingency management (financial incentives) to encourage participation in structured exercise rehabilitation programs. The research deliverables will include clinical validation of an integrated treatment approach designed to improve care engagement and quality of life outcomes for patients with methamphetamine-associated congestive heart failure and methamphetamine-associated pulmonary arterial hypertension. The program specifically targets adaptability to rural settings where geographic barriers limit access to specialty medical and addiction treatment services, directly addressing the significant morbidity, mortality, and healthcare costs associated with these conditions, such as the 840 percent inflation-adjusted increase in methamphetamine-associated congestive heart failure hospitalization costs in California from 2008-2018.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $423.5k | 7/10/26 |